Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma
NCT ID: NCT01569204
Last Updated: 2018-10-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
100 participants
INTERVENTIONAL
2012-10-31
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* to determine complete response rate (CRR) after six cycles of chemotherapy
* to determine complete remission rate (CR/CRr) as final treatment outcome after completion of treatment
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
HD21 for Advanced Stages
NCT02661503
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma
NCT00049595
Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma
NCT01251107
Brentuximab Vedotin with Adriamycin, Vinblastine and Dacarbazine for Patients Aged 18-59 Years with Untreated Advanced-stage Classical Hodgkin Lymphoma: a Real-life Experience
NCT06857500
Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma
NCT00284271
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BrECAPP
modified BEACOPP by omitting Bleomycin and adding Brentuximab Vedotin
Etoposide
Cyclophosphamide
Doxorubicin
Prednisone
Procarbazine
Brentuximab Vedotin
BrECADD
modified BEACOPP by omitting Bleomycin, Procarbazine and Prednisone and adding Brentuximab Vedotin, Dacarbazine and Dexamethasone
Etoposide
Cyclophosphamide
Doxorubicin
Dexamethasone
Dacarbazine
Brentuximab Vedotin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Etoposide
Cyclophosphamide
Doxorubicin
Prednisone
Procarbazine
Dexamethasone
Dacarbazine
Brentuximab Vedotin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* First diagnosis, no previous treatment, age: 18-60 years
* Stage IIB with large mediastinal mass and/or extranodal lesions, stage III or IV disease
Exclusion Criteria
* Previous malignancy
* Prior chemotherapy or radiation
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Cologne
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Dr. Peter Borchmann
Prof.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter Borchmann, Prof.
Role: PRINCIPAL_INVESTIGATOR
University of Cologne, German Hodgkin Study Group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
1st Dept. of Medicine, Cologne University Hospital
Cologne, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Homepage GHSG
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Targeted BEACOPP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.